Huakang Biomedical Holdings Company Limited (HKG:8622)
Hong Kong · Delayed Price · Currency is HKD 0.3900
+0.0100 (2.63%)
Aug 29, 2025, 3:58 PM HKT
HKG:8622 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 25.77 | 25.36 | 24.63 | 25.33 | 26.13 | 21.97 | Upgrade | |
Revenue Growth (YoY) | 2.74% | 2.96% | -2.77% | -3.05% | 18.94% | -13.76% | Upgrade |
Cost of Revenue | 8.27 | 8.29 | 8.54 | 8.42 | 9.67 | 7.25 | Upgrade |
Gross Profit | 17.5 | 17.07 | 16.09 | 16.91 | 16.46 | 14.72 | Upgrade |
Selling, General & Admin | 19.83 | 19.29 | 18.49 | 18.75 | 17.7 | 17.32 | Upgrade |
Research & Development | 2.67 | 2.83 | 2.55 | 2.48 | 2.44 | 2.25 | Upgrade |
Operating Expenses | 22.67 | 22.08 | 22.81 | 21.61 | 20.77 | 23.02 | Upgrade |
Operating Income | -5.17 | -5.01 | -6.71 | -4.7 | -4.32 | -8.3 | Upgrade |
Interest Expense | -0.1 | -0.09 | -0.05 | -0.06 | -0.1 | -0.07 | Upgrade |
Interest & Investment Income | 0.52 | 0.51 | 0.4 | 0.41 | 0.18 | 0.19 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -0.04 | Upgrade |
Currency Exchange Gain (Loss) | -0.09 | 0.24 | 0.25 | 0.86 | -0.26 | -1.07 | Upgrade |
Other Non Operating Income (Expenses) | 0.1 | 0.19 | 0.33 | 0.48 | 0.6 | 0.47 | Upgrade |
EBT Excluding Unusual Items | -4.75 | -4.16 | -5.78 | -3.01 | -3.9 | -8.83 | Upgrade |
Asset Writedown | - | - | - | - | - | -2.56 | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.01 | Upgrade |
Pretax Income | -4.75 | -4.16 | -5.78 | -3.01 | -3.9 | -11.37 | Upgrade |
Income Tax Expense | - | - | - | 0.07 | 0.32 | 0.26 | Upgrade |
Net Income | -4.75 | -4.16 | -5.78 | -3.08 | -4.22 | -11.63 | Upgrade |
Net Income to Common | -4.75 | -4.16 | -5.78 | -3.08 | -4.22 | -11.63 | Upgrade |
Shares Outstanding (Basic) | 501 | 482 | 416 | 405 | 400 | 400 | Upgrade |
Shares Outstanding (Diluted) | 501 | 482 | 416 | 405 | 400 | 400 | Upgrade |
Shares Change (YoY) | 13.53% | 15.98% | 2.80% | 1.16% | - | - | Upgrade |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | Upgrade |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | Upgrade |
Free Cash Flow | -3.71 | -5.05 | -1.55 | 0.64 | -4.33 | -5.67 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.00 | 0.00 | -0.01 | -0.01 | Upgrade |
Gross Margin | 67.91% | 67.32% | 65.34% | 66.77% | 62.98% | 67.00% | Upgrade |
Operating Margin | -20.05% | -19.76% | -27.26% | -18.54% | -16.52% | -37.77% | Upgrade |
Profit Margin | -18.43% | -16.40% | -23.48% | -12.14% | -16.15% | -52.93% | Upgrade |
Free Cash Flow Margin | -14.41% | -19.93% | -6.29% | 2.51% | -16.57% | -25.79% | Upgrade |
EBITDA | -3.74 | -3.49 | -5.11 | -2.92 | -2.82 | -6.45 | Upgrade |
EBITDA Margin | -14.50% | -13.75% | -20.76% | -11.52% | -10.80% | -29.36% | Upgrade |
D&A For EBITDA | 1.43 | 1.52 | 1.6 | 1.78 | 1.5 | 1.85 | Upgrade |
EBIT | -5.17 | -5.01 | -6.71 | -4.7 | -4.32 | -8.3 | Upgrade |
EBIT Margin | -20.05% | -19.76% | -27.26% | -18.54% | -16.52% | -37.77% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.